Welltica+ on MSN
Tiny implant eliminates bladder cancer in 82% of patients
A new slow-release implant has shown unprecedented success in wiping out bladder cancer in more than 80 percent of patients, ...
An innovative new treatment option for bladder cancer, recently approved by the U.S. Food and Drug Administration, has been performed for the first time in Maryland.
EnGene Holdings reported positive preliminary data from an ongoing Phase 2 trial of its detalimogene voraplasmid drug to treat a form of bladder cancer. Shares were up 65% to $9.93 in premarket ...
Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...
A slow drug-release system has proven highly effective in treating certain bladder cancer patients whose tumors were previously unresponsive to therapy. A new targeted drug delivery system known as TA ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Non Muscle Invasive Bladder Cancer - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This "Non Muscle ...
It can be annoying if your bladder seems to work overtime and you're headed to the bathroom more often than you'd like, but that doesn't necessarily mean you need medication or that you even have a ...
The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.
A new study suggests that more women are being prescribed beta-3 agonists over anticholinergics for the treatment of overactive bladder (OAB), suggesting that more clinicians may be choosing this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback